Acquisition synergies Current owner Repligen acquisition (2021) suggests potential cross-sell opportunities for Avitide’s affinity purification solutions within Repligen’s existing bioprocessing customer base and portfolio.

Vaccine purification demand Recent launch of affinity resin for COVID-19 vaccine manufacturing indicates readiness to serve pandemic response programs; target manufacturers and contract developers expanding or diversifying vaccine pipelines.

Rapid onboarding Avitide advertises a three-month concept-to-resin delivery timeline, appealing to teams seeking faster development timelines and tighter process economics in downstream purification.

Quality and continuity ISO 9001:2015 systems with audited continuity of supply position Avitide as a dependable supplier for critical biopharma purification resins, beneficial in regulated manufacturing environments.

Diversified applications Experience across enzymes, antibodies, cell therapies, vaccines, and gene therapy vectors opens cross-sell paths into multiple biopharma modalities and evolving bioprocess platforms.